NSP NEWS

(=NSP NEWS) = SK Pharmteco, SK’s Contract Development Manufacturing Organization(CDMO) subsidiary completed its second plant in Europe for Cell and Gene Therapy(CGT) and will accelerate its expansion into the global market.

SK Pharmteco announced that Yposkesi, a subsidiary of the French-based CDMO for cell and gene therapy, has completed its second plant with large-scale commercial production facilities.

The second plant, located in Genopole, France, along with the first plant, is a 5,000 square meter facility designed in accordance with the European and American cGMP(Advanced Pharmaceutical Manufacturing and Quality Control) guidelines. As a result, Yposkesi has secured a facility with a total area of 10,000 square meters, which is the largest in Europe.

The second plant will produce Adeno-associated virus(AAV) and Lentivirus vector(LV), which are viral vectors most commonly used in cell and gene therapy, for both clinical and commercial use.

Viral vectors are carriers that deliver genes into target cells and the body, and Adeno-associated viruses are mainly used for gene therapy and Lentivirus vectors for cell therapy.

Based on the technology that can produce high-quality viral vectors even in mass commercial production, Yposkesi has already signed a number of production contracts at the second plant and plans to start mass production in earnest from 2024.